Carlsmed, Inc. CARL

Updated: 10 Aug 2026

NASDAQ | Technology | Medical Technology and AI

No signal published yet

We already track Carlsmed and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Carlsmed free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Technology
Sector
Medical Technology and AI
We're already tracking Carlsmed, Inc. — here are the latest events we've registered

Recent News

  • On August 5, 2026, Carlsmed reported its second quarter 2026 financial results, generating $18.9 million in revenue, a 57% increase year-over-year. The company also raised its full-year 2026 revenue guidance to a range of $74 million to $78 million.

What Firelda Watch includes for Carlsmed, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Carlsmed, Inc. will be delivered in the same format.

Want to follow Carlsmed, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Carlsmed free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Carlsmed, Inc. CARL
Carlsmed — follow and we'll monitor it
Follow Carlsmed free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.